Compare EQT Corporation Common Stock (EQT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EQT Corporation Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? EQT Corporation Common Stock trades at $52.49 (market cap $34.05B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: EQT Corporation Common Stock is far larger — about 35× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and EQT Corporation Common Stock pays a 1.21% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EQT Corporation Common Stock for 1 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EQT | MRVI | |
|---|---|---|
Market Cap | $34.05B | $972.90M |
Volume | 4,662,584 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $67.93 | $9.00 |
52-Week Low | $48.56 | $2.83 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $39.59B | $1.08B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQT trades at $54.43, up 2.27% today, with a bullish technical outlook and strong analyst consensus. The stock benefits from robust profitability, with a net income margin of 28.61% and a P/E ratio of 12.63. Recent news highlights a dividend increase and positive natural gas market tailwinds, while institutional buying activity supports sentiment. Earnings have mostly beaten expectations, with Q3 2026 results pending.
The outlook for EQT is positive, driven by operational efficiency, favorable natural gas demand, and a strong balance sheet. Risks include commodity price volatility and execution of growth plans. With a consensus price target of $70.33 implying significant upside, the stock presents a compelling opportunity for investors seeking exposure to the energy sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EQT Corporation Common Stock
EQT produces and transports natural gas, with production and midstream operations in the Appalachian Basin. Its operations are concentrated in Pennsylvania, West Virginia, and Ohio.
Read more on EQT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
